Navigation Links
Soligenix Announces Issuance of Hong Kong Patent for its LPM(TM) Oral Drug Delivery Technology
Date:2/17/2010

his results in a drug-delivery system that is a thermodynamically stable clear dispersion of the water-soluble drug in the lipid phase. But unlike water-in-oil systems, stabilized reverse micelles do not depend on the presence of other surfactants and are thermodynamically stable. In the LPM™ system, water-soluble drugs are contained in the water space in the core of the micelles and are protected against degradation.

Soligenix anticipates proceeding towards clinical development of an oral form of the peptide hormone drug leuprolide using the LPM™ technology. Leuprolide is a synthetic peptide agonist of gonadotropin releasing hormone (GnRh) that is used in treatment of endometriosis in women and prostate cancer in men. In preclinical studies in rats and dogs, Soligenix has demonstrated that the LPM™ technology results in high systemic bioavailability of intestinally absorbed leuprolide. In both animal models, the bioavailability of leuprolide ranged from 20 to 40 percent, compared to less than 5 percent for the control oral solution. Leuprolide is one of the most widely used anti-cancer agents for advanced prostate cancer in men. Injectable forms of leuprolide marketed under trade names such as Lupron® and Eligard® had worldwide sales of approximately $1.7 billion in 2006. Injectable leuprolide is also widely used in non-cancer indications, such as endometriosis in women (a common condition in which cells normally found in the uterus become implanted in other areas of the body), uterine fibroids in women (noncancerous growths in the uterus) and central precocious puberty in children (a condition causing children to enter puberty too soon). Leuprolide is currently available only in injectable, injectable depot and subcutaneous implant routes of delivery.

LPM™ is thought to promote intestinal absorption through the action of the micelles to open up small channels that allow only
'/>"/>

SOURCE Soligenix, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Soligenix Announces Publication of Positive Stability Results with RiVax(TM), its Vaccine Against Ricin Toxin
2. Soligenix Announces Publication of Positive Pre-Clinical Results with RiVax(TM), Its Vaccine Against Ricin Toxin
3. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
4. Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
7. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
8. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
9. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
10. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
11. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... May 21, 2013 On its tenth ... product developments at the Special Libraries Association PHTD meeting in ... focus on product literature databases and workflow solutions for the ... said founding director Nigel Johnson . "At ... to our clients and what better forum to announce them ...
(Date:5/21/2013)... May 21, 2013  Zacks.com announces the list of ... Zacks Equity Research analysts discuss the latest news and ... featured in the blog include Actavis, Inc.,s (NYSE: ... SA (NYSE: TOT ), Petrobras (NYSE: PBR ... (Logo: http://photos.prnewswire.com/prnh/20101027/ZIRLOGO ) ...
(Date:5/21/2013)... RICHLAND, Wash. , May 21, 2013  IsoRay, ... announced today that it has entered into an exclusive ... of IsoRay,s complete product line in Greece ... innovator in seed brachytherapy and medical radioisotope applications for ... cancer and gynecologic ("gyn") cancer. IASIS ...
Breaking Medicine Technology:Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 2Pi2 Solutions' 10th Anniversary Heralds New Corporate Image as Platinum Sponsor of SLA PHT Meeting in Philadelphia 3The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 2The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 3The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 4The Zacks Analyst Blog Highlights: Actavis, BP, Total, Petrobras and Devon Energy 5IsoRay Announces A New International Distributor For Greece 2IsoRay Announces A New International Distributor For Greece 3
(Date:5/21/2013)... May 21, 2013 DISCcert has served ... how to use 17 DISC applications at the July ... natural progression. , The July 25 & 26th DISC ... 17 ways of applying DISC. The time-tested, proven support ... The user-friendly DISC training materials ; worksheets, ...
(Date:5/21/2013)... New York (PRWEB) May 21, 2013 ... protecting the rights of victims injured by defective medical ... of Bone & Joint Surgery on May 15, 2013. ... be used to identify complications that occur in patients ... symptoms of failure. ( http://www.jbjs.org/article.aspx?articleid=1684770 ) ...
(Date:5/21/2013)... May 2013, Paris, France: The Orsiro stent, which ... a biodegradable polymer, demonstrated non-inferiority to the Xience ... of in-stent late lumen loss at nine months ... at EuroPCR 2013 today. , The BIOFLOW-II substudy ... (OCT) to quantitatively assess neointimal hyperplasia and stent ...
(Date:5/21/2013)... 2013 Phoseon Technology will present their ... 20th Annual IMI European Ink Jet Conference (June ... Phoseon continues to invest in product development to enable ... UV LED curing in printing applications. Phoseon currently ... market offering both air cooled and water cooled solutions ...
(Date:5/21/2013)... 2013) A paper recently published in the ... physicians and scientists at the University of Colorado School ... for pulmonary fibrosis can be used to identify individuals ... looked at a fairly common variant of the gene ... the mucous produced by the bronchial tubes. While this ...
Breaking Medicine News(10 mins):Health News:DISCcert Offers 17 Applications in Coming DISC Certification 2Health News:DISCcert Offers 17 Applications in Coming DISC Certification 3Health News:DISCcert Offers 17 Applications in Coming DISC Certification 4Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 2Health News:Parker Waichman LLP Comments on New Study Showing that MRI is Useful for Predicting Failure of Metal-on-Metal Hip Implants 3Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Researchers find genetic risk factor for pulmonary fibrosis 2
... number of youngsters trying to find their love live on the ... or BBS. // ,Li Mei met her boyfriend Liu Wei ... well-known Shuimu Tsinghua BBS (SMTH), which is run by students from ... engaged. ,"BBS is a bridge for our romance," said ...
... the survival rates has been documented in Acute Coronary ... analysis reported at the Society for Cardiovascular Angiography and ... May 10–13. ,By combining data from nine ... than in combination, the analysis was able to put ...
... nanomolcecules called ‘nanolipoblockers’ that guard against bad cholesterol. ... that they offer a local therapeutic effect,// aimed ... in cardiac patients. These nanoengineered molecules, which represent ... could soon join the fight against heart disease, ...
... A survey by the British Dental Health Foundation has found ... comes into their hand to clean off food debris// struck ... and knives are in common use, the survey said. ... food stuck in between their teeth giving rise to oral ...
... Commission will soon come up with recommendations to overhaul ... make it more competitive//, and to accommodate more students, ... come up with recommendations on the undergraduate educational set-up ... adding that a group has also been appointed to ...
... give drugs to end the life of those who are ... parliament//. The assisted dying bill of Britain was based on ... lethal drugs to patients who are suffering unbearably and have ... administered by the patients to themselves. But after a seven-hour ...
Cached Medicine News:Health News:Web Romance Is Catching Up Among The Youths In China 2Health News:Statin Therapy in Patients with Acute Coronary Syndrome Improves Survival 2Health News:Nanotechnology Could Revolutionize Cardiac Treatment 2Health News:Nanotechnology Could Revolutionize Cardiac Treatment 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: